News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
|
Followers
|
21
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
431
|
|
Created
|
06/06/12
|
Type
|
Free
|
| Moderators | |||
Corindus Vascular Robotics, Inc.(CVRS) is a global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The Company?s FDA-cleared CorPath System is the first medical device that offers interventional cardiologists PCI procedure control from a radiation protective interventional cockpit. With the CorPath System, Corindus Vascular Robotics brings robotic precision to PCI procedures to help optimize clinical outcomes and minimize the costs associated with complications through of improper stent placement with manual PCI procedures.
Dr. Vijay Lyer's Story
Interventional cardiologist, Dr. Vijay Iyer, has spent his career providing lifesaving care to his patients, all while wearing heavy lead apparel to protect himself from the harmful effects of radiation exposure required for his procedures. Unfortunately, the lead apparel required during percutaneous coronary interventions, or PCI, and other procedures in the cath lab has led to serious spinal injuries for Dr. Iyer. After four back surgeries, Dr. Iyer was faced with the grim reality that one more surgery may end his career in the cath lab. The orthopedic injuries he faced are unfortunately very common among interventional cardiologists and other cath lab personnel with 60% of interventionalists with more than 20 years in the lab experiencing spinal issues.
Dr. Iyer was committed to finding a solution that would allow him to continue in interventional cardiology without the need for heavy lead apparel. This video highlights how Dr. Iyer is avoiding further injury by routinely utilizing CorPath, the first robotic system cleared for PCI, which enables him to provide a high level of care for his patients from the safety of a radiation-protected interventional cockpit.
http://www.corindus.com/news-events/press-releases/september-16-2015
How it works
http://www.corindus.com/corpath-grx/how-it-works
| Market Value1 | $286,233,809 | a/o Jun 13, 2017 | |
| Authorized Shares | 250,000,000 | a/o Dec 31, 2014 | |
| Outstanding Shares | 187,080,921 | a/o May 08, 2017 |
| Common Stock, $0.0001 Par Value | Additional Paid-in | Accumulated | ||||||||||||||||||
| Shares | Amount | Capital | Deficit | Total | ||||||||||||||||
| Balance at December 31, 2016 | 119,025,221 | $ | 12 | $ | 150,776 | $ | (146,718 | ) | $ | 4,070 | ||||||||||
| Stock-based compensation expense | — | — | 792 | — | 792 | |||||||||||||||
| Issuance of common stock in connection with private placement of common stock, net of issuance costs of $415 | 68,055,700 | 7 | 44,604 | — | 44,611 | |||||||||||||||
| Net loss | — | — | — | (9,885 | ) | (9,885 | ) | |||||||||||||
| Balance at March 31, 2017 | 187,080,921 | $ | 19 | $ | 196,172 | $ | (156,603 | ) | $ | 39,588 | ||||||||||
